Capital World Investors continued to hold its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,429,000 shares of the biopharmaceutical company’s stock at the close of the second quarter. Capital World Investors owned about 7.94% of Xenon Pharmaceuticals worth $4,501,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Sabby Management LLC purchased a new position in shares of Xenon Pharmaceuticals in the first quarter valued at about $1,186,000. KCG Holdings Inc. purchased a new position in shares of Xenon Pharmaceuticals in the first quarter valued at about $122,000. K2 Principal Fund L.P. increased its position in shares of Xenon Pharmaceuticals by 40.6% in the second quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock valued at $518,000 after acquiring an additional 47,535 shares during the period. Endurant Capital Management LP purchased a new position in shares of Xenon Pharmaceuticals in the first quarter valued at about $1,363,000. Finally, Renaissance Technologies LLC increased its position in shares of Xenon Pharmaceuticals by 90.1% in the first quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock valued at $868,000 after acquiring an additional 102,890 shares during the period. Hedge funds and other institutional investors own 55.30% of the company’s stock.
Xenon Pharmaceuticals Inc. (XENE) opened at 3.10 on Wednesday. Xenon Pharmaceuticals Inc. has a 52-week low of $2.25 and a 52-week high of $9.95. The stock’s market cap is $55.79 million. The firm has a 50 day moving average of $3.05 and a 200-day moving average of $3.50.
Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.03). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.38 million. Xenon Pharmaceuticals had a negative return on equity of 47.53% and a negative net margin of 3,489.63%. Equities analysts anticipate that Xenon Pharmaceuticals Inc. will post ($0.97) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Xenon Pharmaceuticals Inc. (XENE) Holdings Maintained by Capital World Investors” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.com-unik.info/2017/10/11/xenon-pharmaceuticals-inc-xene-holdings-maintained-by-capital-world-investors.html.
In other news, major shareholder Bvf Partners L. P/Il bought 41,344 shares of the stock in a transaction dated Monday, August 14th. The stock was purchased at an average price of $2.70 per share, for a total transaction of $111,628.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mohammad Azab bought 10,000 shares of the stock in a transaction dated Friday, September 22nd. The stock was purchased at an average price of $2.95 per share, with a total value of $29,500.00. Following the acquisition, the director now directly owns 21,210 shares in the company, valued at approximately $62,569.50. The disclosure for this purchase can be found here. Insiders bought a total of 210,739 shares of company stock valued at $568,975 in the last 90 days. Company insiders own 9.40% of the company’s stock.
XENE has been the topic of a number of analyst reports. Jefferies Group LLC set a $5.00 price objective on shares of Xenon Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 4th. Canaccord Genuity restated a “buy” rating and issued a $5.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, June 27th. Finally, Zacks Investment Research upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 5th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $10.63.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
What are top analysts saying about Xenon Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Xenon Pharmaceuticals Inc. and related companies.